## UNITED STATES JUDICIAL PANEL MULTIDISTRICT LITIGATION

IN RE: LURASIDONE PATENT LITIGATION MDL No. 2839

(SEE ATTACHED SCHEDULE)

## ORDER DEEMING MOTION MOOT AND VACATING THE MAY 31, 2018, HEARING SESSION ORDER

Before the Panel is a motion by plaintiffs Sumitomo Dainippon Pharma Co., Ltd., and Sunovion Pharmaceuticals Inc., seeking centralization, pursuant to 28 U.S.C. § 1407, in the United States District Court for the District of New Jersey of the actions on the attached schedule for coordinated or consolidated pretrial proceedings. The Panel has now been advised that plaintiffs have voluntarily dismissed all of the non-District of New Jersey actions on the attached schedule, thus depriving this litigation of its multidistrict character.

IT IS THEREFORE ORDERED that the motion for transfer under 28 U.S.C. § 1407 is DEEMED MOOT.

IT IS FURTHER ORDERED that the Hearing Session Order and the attached Schedule filed on April 16, 2018, are VACATED insofar as they relate to this matter.

FOR THE PANEL:

Clerk of the Panel

## UNITED STATES JUDICIAL PANEL on MULTIDISTRICT LITIGATION

IN RE: LURASIDONE PATENT LITIGATION MDL No. 2839

## **SCHEDULE A**

<b>DIST</b>	DIV.	<u>C.A. NO.</u>	<u>CASE CAPTION</u>
DELAWARE			
DE	1	18-00256	Sumitomo Dainippon Pharma Co., Ltd., et al. v. Amnea Pharmaceuticals, LLC
DE	1	18-00369	Sumitomo Dainippon Pharma Co., Ltd., et al, v. First Time US Generics, LLC
NORTH CAROLINA MIDDLE			
NCM	1	18-00185	Sumitomo Dainippon Pharma Co., Ltd, et Al. V. Accord Healthcare, Inc.
NEW JERSEY			
NJ	2	18-02065	Sumitomo Dainippon Pharma Co., Ltd. et al v. Emcure Pharmaceuticals Ltd
NJ	2	18-02620	Sumitomo Dainippon Pharma Co., Ltd. et al. v. Aurobindo Pharma Ltd., et al.
NEW YORK EASTERN			
NYE	1	18-01444	Sumitomo Dainippon Pharma Co., Ltd., et al. v. InvaGen Pharmaceuticals, Inc.